티오테파

용도

• Intracavitary use for neoplastic effusions or systemically for adjunctive therapy of carcinomas

투여 방법

가능한 부작용

• Leukopenia (most common)
• Thrombocytopenia
• Anemia
• Pancytopenia
• Vomiting
• Diarrhea
• Stomatitis
• Intestinal ulceration
• Dizziness (reported in humans)
• Headache (reported in humans)

주의사항 및 금기

• Hypersensitivity to thiotepa
• Pregnancy (teratogenic and mutagenic - FDA Category D)
• > **WARNING:** Thiotepa has a very low therapeutic index and should only be administered by clinicians experienced with cytotoxic agents. * **Organ Dysfunction:** Use with extreme caution in patients with hepatic dysfunction or renal function impairment (dosage adjustment may be necessary). * **Bone Marrow:** Weigh risks vs. benefits in patients with pre-existing bone marrow depression, active infections, or tumor cell infiltration of the bone marrow. * **Urolithiasis:** Use cautiously in patients with a history of urate urinary stones, as thiotepa may increase serum uric acid levels. * **Nursing:** It is unknown if thiotepa enters maternal milk; use of a milk replacer is strongly recommended for nursing bitches or queens.

약물 상호작용

• Immunosuppressive drugs (e.g., azathioprine, cyclophosphamide, corticosteroids): May increase the risk of severe infections due to additive immunosuppression.
• Myelosuppressive drugs (e.g., chloramphenicol, flucytosine, amphotericin B, colchicine): Extreme caution required; bone marrow depression may be additive and lead to severe pancytopenia.
• Live Vaccines: Increased risk of vaccine-induced infection or reduced vaccine efficacy; use with extreme caution, if at all.

자주 묻는 질문